215 related articles for article (PubMed ID: 35156727)
1. The PAX5-JAK2 translocation acts as dual-hit mutation that promotes aggressive B-cell leukemia via nuclear STAT5 activation.
Jurado S; Fedl AS; Jaritz M; Kostanova-Poliakova D; Malin SG; Mullighan CG; Strehl S; Fischer M; Busslinger M
EMBO J; 2022 Apr; 41(7):e108397. PubMed ID: 35156727
[TBL] [Abstract][Full Text] [Related]
2. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.
Schinnerl D; Fortschegger K; Kauer M; Marchante JR; Kofler R; Den Boer ML; Strehl S
Blood; 2015 Feb; 125(8):1282-91. PubMed ID: 25515960
[TBL] [Abstract][Full Text] [Related]
3. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.
Heltemes-Harris LM; Willette MJ; Ramsey LB; Qiu YH; Neeley ES; Zhang N; Thomas DA; Koeuth T; Baechler EC; Kornblau SM; Farrar MA
J Exp Med; 2011 Jun; 208(6):1135-49. PubMed ID: 21606506
[TBL] [Abstract][Full Text] [Related]
4. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
Jamrog L; Chemin G; Fregona V; Coster L; Pasquet M; Oudinet C; Rouquié N; Prade N; Lagarde S; Cresson C; Hébrard S; Nguyen Huu NS; Bousquet M; Quelen C; Brousset P; Mancini SJC; Delabesse E; Khamlichi AA; Gerby B; Broccardo C
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10357-10362. PubMed ID: 30257940
[No Abstract] [Full Text] [Related]
5. LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients.
Cazzaniga V; Bugarin C; Bardini M; Giordan M; te Kronnie G; Basso G; Biondi A; Fazio G; Cazzaniga G
Oncotarget; 2015 Jan; 6(3):1569-81. PubMed ID: 25595912
[TBL] [Abstract][Full Text] [Related]
6. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia.
Liu GJ; Cimmino L; Jude JG; Hu Y; Witkowski MT; McKenzie MD; Kartal-Kaess M; Best SA; Tuohey L; Liao Y; Shi W; Mullighan CG; Farrar MA; Nutt SL; Smyth GK; Zuber J; Dickins RA
Genes Dev; 2014 Jun; 28(12):1337-50. PubMed ID: 24939936
[TBL] [Abstract][Full Text] [Related]
7. EBF1-JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity.
Kojima Y; Kawashima F; Yasuda T; Odaira K; Inagaki Y; Yamada C; Muraki A; Noura M; Okamoto S; Tamura S; Iwamoto E; Sanada M; Matsumura I; Miyazaki Y; Kojima T; Kiyoi H; Tsuzuki S; Hayakawa F
Int J Hematol; 2023 Jul; 118(1):65-74. PubMed ID: 37149540
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus.
Souabni A; Jochum W; Busslinger M
Blood; 2007 Jan; 109(1):281-9. PubMed ID: 16968900
[TBL] [Abstract][Full Text] [Related]
9. Infection Exposure is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of Pax5-Inherited Susceptibility.
Martín-Lorenzo A; Hauer J; Vicente-Dueñas C; Auer F; González-Herrero I; García-Ramírez I; Ginzel S; Thiele R; Constantinescu SN; Bartenhagen C; Dugas M; Gombert M; Schäfer D; Blanco O; Mayado A; Orfao A; Alonso-López D; Rivas Jde L; Cobaleda C; García-Cenador MB; García-Criado FJ; Sánchez-García I; Borkhardt A
Cancer Discov; 2015 Dec; 5(12):1328-43. PubMed ID: 26408659
[TBL] [Abstract][Full Text] [Related]
10. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
Walz C; Ahmed W; Lazarides K; Betancur M; Patel N; Hennighausen L; Zaleskas VM; Van Etten RA
Blood; 2012 Apr; 119(15):3550-60. PubMed ID: 22234689
[TBL] [Abstract][Full Text] [Related]
11. Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development.
Fortschegger K; Anderl S; Denk D; Strehl S
Mol Cancer Res; 2014 Apr; 12(4):595-606. PubMed ID: 24435167
[TBL] [Abstract][Full Text] [Related]
12. PAX5 fusion genes in acute lymphoblastic leukemia: A literature review.
Fouad FM; Eid JI
Medicine (Baltimore); 2023 May; 102(20):e33836. PubMed ID: 37335685
[TBL] [Abstract][Full Text] [Related]
13. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
[TBL] [Abstract][Full Text] [Related]
14. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T
J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972
[TBL] [Abstract][Full Text] [Related]
15. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
Bousquet M; Broccardo C; Quelen C; Meggetto F; Kuhlein E; Delsol G; Dastugue N; Brousset P
Blood; 2007 Apr; 109(8):3417-23. PubMed ID: 17179230
[TBL] [Abstract][Full Text] [Related]
16. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer.
An Q; Wright SL; Konn ZJ; Matheson E; Minto L; Moorman AV; Parker H; Griffiths M; Ross FM; Davies T; Hall AG; Harrison CJ; Irving JA; Strefford JC
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17050-4. PubMed ID: 18957548
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
18. EBF-regulating Pax5 transcription is enhanced by STAT5 in the early stage of B cells.
Hirokawa S; Sato H; Kato I; Kudo A
Eur J Immunol; 2003 Jul; 33(7):1824-9. PubMed ID: 12811842
[TBL] [Abstract][Full Text] [Related]
19. One missense mutation in exon 2 of the PAX5 gene in Iran.
Yazdanparast S; Khatami SR; Galehdari H; Jaseb K
Genet Mol Res; 2015 Dec; 14(4):17768-75. PubMed ID: 26782422
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient.
Kanayama T; Imamura T; Mayumi A; Soma E; Sakamoto K; Hayakawa F; Tanizawa A; Kiyokawa N; Hosoi H
Int J Hematol; 2020 Nov; 112(5):714-719. PubMed ID: 32656633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
